India M&As Overtook PE Activity In 2022, Deal Momentum To Continue In 2023

Biocon-Viatris Deal Largest

India had a busy deals calendar in 2022, with companies led by Biocon striking large M&A deals while PE activity declined. In Vivo's sister publication Scrip pieced together data for infographics on these deals. A multitude of factors is expected to keep the momentum going in 2023.  

India
Indian Pharma's M&A Activity Expected To Continue In 2023 • Source: Shutterstock

In 2022, Indian companies seem to have followed financial economist and investor Robert Haugen’s philosophy as they added missing bits, strengthened weak spots or built on their strengths for merger and acquisition (M&A) activity.

"In going directly to investment heaven, you build your portfolio as you would build a wonderful company through a merger...

More from Global Vision

More from In Vivo

Strategic Surprises: The Drugs That Rewrote The Forecasts

 

Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

 

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By 

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.